Daily Judi: Wednesday, September 7, 2022
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
With the approval of a new inhaled COVID-19 vaccine in China, and over 100 oral or nasal vaccines in development internationally, Nature asks if this could change the state of the pandemic.
Reporter Olivia Goldhill takes a long look at a new healthcare company launched by tobacco giant, Philip Morris. (Stat)
September is Alopecia Awareness Month—landmarks around the country, such as Boston’s Longfellow Bridge, are lit blue to show support and bring attention to the autoimmune condition. Concert Pharma is promoting alopecia awareness with a campaign, #LightItUpBlue4AlopeciaAreata, encouraging social media users to participate. (Fierce Pharma)
The CNS Summit 2022 will be held on November 17–20, in Boca Raton, Florida. Created as "a community of innovators and industry leaders who are not afraid to challenge the status quo," CNS was founded in 2009 to advance clinical development, focused on collaboration and innovation. Team Judi will be there!
We also hope to see you this September 13-14, in Boston, for DPHARM: Disruptive Innovations to Advance Clinical Trials, walking distance from our North End headquarters.
Attending the annual conference of the Society for Clinical Data Management in San Antonio, Texas (SCDM2022)? Join AG Mednet's Abraham Gutman in a roundtable discussion on how imaging quality control automation improve endpoint data, Monday, September 12, 2022, 1:45 to 2:45 p.m.
Our Culture
“Dossiers and redaction are built within the Judi platform, which helps significantly with adjudication management— and the client collaborates on the process.”
–Jess, Program Manager
About Judi
Judi empowers and enhances the world's clinical trial ecosystems. Our cloud-based platform has 110,000 users across 140 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.
